BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–100 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Mutation7
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6305 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6306 This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID1704 A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC) PMID 22586653 · Bertotti et al., 2011 · Open in CIViC	civic
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2187 This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were K… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1404 A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targ… (full text at CIViC) PMID 25673558 · Pietrantonio et al., 2015 · Open in CIViC	civic
Irinotecan	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6304 This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Oxaliplatin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6303 This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF V600E24
Bevacizumab + Capecitabine + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2121 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=… (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic
Binimetinib + Cetuximab + EncorafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID7260 In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the sa… (full text at CIViC) Open in CIViC	civic
BRAF D594G3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Does Not Support Resistance	3	accepted	EID2201 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID4472 In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to b… (full text at CIViC) PMID 26989027 · Hsu et al., 2016 · Open in CIViC	civic
Cetuximab
BRAF V6006
Cetuximab + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1598 Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with B… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1415 In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed partia… (full text at CIViC) PMID 26392102 · Corcoran et al., 2015 · Open in CIViC	civic
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF D594K2
Irinotecan	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6402 The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Oxaliplatin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6403 Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Amplification1
Dabrafenib + PanitumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2929 Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant … (full text at CIViC) PMID 25673644 · Ahronian et al., 2015 · Open in CIViC	civic
BRAF G466V2
Irinotecan + PanitumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID7552 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7553 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells … (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
BRAF G596R1
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	1	accepted	EID4729 In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing muta… (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION, USP (DIN 02452421) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 22, 2024	health-canada-dpd
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528789) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 28, 2024	health-canada-dpd
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501279) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 251–300 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05425940	Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer(STELLAR-303)	active not recruiting	Phase 3	901	ExelixisINDUSTRY	16	Jul 17, 2026	clinicaltrials
NCT01087554	Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer	active not recruiting	Phase 1	249	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT02525757	MPDL3280A With Chemoradiation for Lung Cancer	active not recruiting	Phase 2	52	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	Phase 2	59	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	Phase 1 / Phase 2	37	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03599752	Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases	active not recruiting	Phase 2	40	M.D. Anderson Cancer CenterOTHER	2	Jul 16, 2026	clinicaltrials
NCT04188145	A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer(BEVAMAINT)	active not recruiting	Phase 3	400	Centre Hospitalier Universitaire DijonOTHER	1	Jul 16, 2026	clinicaltrials
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	recruiting	Phase 1	43	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	recruiting	Phase 2	270	Corcept TherapeuticsINDUSTRY	8	Jul 16, 2026	clinicaltrials
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	recruiting	Phase 2	144	Ono Pharmaceutical Co., Ltd.INDUSTRY	6	Jul 16, 2026	clinicaltrials
NCT05000294	Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types	recruiting	Phase 1 / Phase 2	29	University of FloridaOTHER	1	Jul 13, 2026	clinicaltrials
NCT03148418	A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)	active not recruiting	Phase 3	382	Hoffmann-La RocheINDUSTRY	32	Jul 10, 2026	clinicaltrials
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	recruiting	Phase 1 / Phase 2	85	Mayo ClinicOTHER	1	Jul 10, 2026	clinicaltrials
NCT06109779	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)	active not recruiting	Phase 3	760	AstraZenecaINDUSTRY	21	Jul 10, 2026	clinicaltrials
NCT07637851	Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar)	not yet recruiting	Phase 1 / Phase 2	43	ARCAGY/ GINECO GROUPOTHER	1	Jul 10, 2026	clinicaltrials
NCT07689539	Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation	not yet recruiting	Phase 3	360	Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY	0	Jul 8, 2026	clinicaltrials
NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	active not recruiting	Early Phase 1	13	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 7, 2026	clinicaltrials
NCT03737643	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O)	active not recruiting	Phase 3	1,407	AstraZenecaINDUSTRY	20	Jul 7, 2026	clinicaltrials
NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	Phase 2	16	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 6, 2026	clinicaltrials
NCT07300150	A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors	recruiting	Phase 1	210	PAQ Therapeutics, Inc.INDUSTRY	2	Jul 6, 2026	clinicaltrials
NCT04576117	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	active not recruiting	Phase 3	300	National Cancer Institute (NCI)NIH	2	Jul 2, 2026	clinicaltrials
NCT04626635	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers(COMBINE-EGFR-1)	active not recruiting	Phase 1 / Phase 2	548	Regeneron PharmaceuticalsINDUSTRY	7	Jul 2, 2026	clinicaltrials
NCT05047250	A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer	active not recruiting	Phase 3	60	Hoffmann-La RocheINDUSTRY	1	Jul 2, 2026	clinicaltrials
NCT06819007	Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01)	recruiting	Phase 3	582	Daiichi SankyoINDUSTRY	25	Jul 2, 2026	clinicaltrials
NCT06839105	A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies	recruiting	Phase 1	214	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Jul 2, 2026	clinicaltrials
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	active not recruiting	Phase 1	5	City of Hope Medical CenterOTHER	1	Jul 1, 2026	clinicaltrials
NCT04835805	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.	active not recruiting	Phase 1	65	Genentech, Inc.INDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT05722886	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol(DETERMINE)	recruiting	Phase 2 / Phase 3	825	Cancer Research UKOTHER	1	Jul 1, 2026	clinicaltrials
NCT07079631	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer	recruiting	Phase 1 / Phase 2	482	BioNTech SEINDUSTRY	5	Jul 1, 2026	clinicaltrials
NCT06794086	SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L)	recruiting	Phase 3	24	Jun HuangOTHER	1	Jun 30, 2026	clinicaltrials
NCT06412198	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	recruiting	Phase 1 / Phase 2	31	M.D. Anderson Cancer CenterOTHER	1	Jun 26, 2026	clinicaltrials
NCT03175432	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	active not recruiting	Phase 2	29	M.D. Anderson Cancer CenterOTHER	1	Jun 25, 2026	clinicaltrials
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	active not recruiting	Phase 1	138	Toray Industries, IncINDUSTRY	2	Jun 23, 2026	clinicaltrials
NCT05005403	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	recruiting	Phase 1	694	AbbVieINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT05584670	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	542	SanofiINDUSTRY	6	Jun 23, 2026	clinicaltrials
NCT05825625	NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing	active not recruiting	Phase 2	35	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER	1	Jun 23, 2026	clinicaltrials
NCT06813079	Using Tumor Models to Determine Treatments	recruiting	Phase 2	25	University Health Network, TorontoOTHER	1	Jun 23, 2026	clinicaltrials
NCT07662031	Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer	not yet recruiting	Phase 2	25	Washington University School of MedicineOTHER	1	Jun 23, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Jun 22, 2026	clinicaltrials
NCT05843188	Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer	active not recruiting	Phase 2	155	University Health Network, TorontoOTHER	1	Jun 22, 2026	clinicaltrials
NCT04722575	Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma(NEO-TIM)	active not recruiting	Phase 2	95	Fondazione Melanoma OnlusOTHER	1	Jun 18, 2026	clinicaltrials
NCT05694715	Combination Therapy in Cancers With Mutations in DNA Repair Genes	recruiting	Phase 1	24	University of California, San FranciscoOTHER	1	Jun 18, 2026	clinicaltrials
NCT06381154	Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer	active not recruiting	Phase 2	24	Mayo ClinicOTHER	1	Jun 18, 2026	clinicaltrials
NCT07339488	Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma(ILDR-03)	recruiting	Phase 2	43	Chuangzhen ChenOTHER	1	Jun 18, 2026	clinicaltrials
NCT05999812	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	active not recruiting	Phase 2	22	University of Texas Southwestern Medical CenterOTHER	1	Jun 17, 2026	clinicaltrials
NCT06106308	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	active not recruiting	Phase 2	110	Cardiff OncologyINDUSTRY	1	Jun 16, 2026	clinicaltrials
NCT06642844	Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL)	recruiting	Phase 3	244	University Hospital, ToursOTHER	1	Jun 16, 2026	clinicaltrials
NCT02671435	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors	active not recruiting	Phase 1 / Phase 2	383	MedImmune LLCINDUSTRY	11	Jun 15, 2026	clinicaltrials
NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03)	active not recruiting	Phase 1 / Phase 2	74	Novartis PharmaceuticalsINDUSTRY	8	Jun 15, 2026	clinicaltrials
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	active not recruiting	Phase 2	48	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)